Asthma and COPD growth
June 19, 2012
THE global market for asthma and
COPD drugs is expected to reach
US$26,965.5 million in 2017, up
from US$25,102.3m in 2010,
according to a new report by
Transparency Market Research.
The report also estimated that
over the seven year period, the
asthma and COPD drug market
would experience a compound
annual growth rate of 1.03%.
Looking at the 2010 figures, the
report found that the asthma drug
segment dominated the overall
asthma and COPD market at
US$14,509.1 million, whilst the
COPD segment was estimated to
be worth US$10,593.2 million.
The COPD market however is
expected to reach US$12.619.8m
in 2017.
Meanwhile, between now and
2017, the report estimates that the
market will grow slowly, primarily
because of expiry of patents of
leading drug brands and price
erosion in the market.
In 2017 however, the report said
that the arrival of a few novel
drugs into the asthma and COPD
market, will be a driver of future
growth, whilst other factors that
will boost the market include long
term use of asthma and COPD
drugs, and an increase in
disposable income and improved
access to medical care facilities in
emerging economies.
According to the report, the
existing asthma and COPD market
is mainly driven by increasing
patient population.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jun 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jun 12
